Tyrosine Kinase Inhibitor Equipment
-
Manufactured by Taiho Oncology, Inc.based in USA
Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations. Non-Small Cell Lung Cancer (Phase 1/2) PHASE ...
-
Manufactured by ALL Chemistry Inc.based in USA
Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol is 1000 times more selective for ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50 >>10 μM). Falnidamol is a pyrimidine-pyrimidine compound with anti-cancer ...
-
Manufactured by Saladax Biomedical, Inc.based in USA
Targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and ...
-
based in SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within ...
-
Manufactured by BridgeBio Pharma, Inc.based in USA
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers. Multiple Phase 3 clinical trials are currently enrolling; please explore www.clinicaltrials.gov for more information. TRUSELTIQ™ (infigratinib) obtained accelerated approval by ...
-
Manufactured by BridgeBio Pharma, Inc.based in USA
Infigratinib (BGJ398), is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven conditions, including achondroplasia, a bone growth disorder in children. Overactivating FGFR3 mutations drive downstream MAPK and STAT1 signaling that aberrates growth plate development, ...
-
based in USA
therapies (up to three to four weeks) and no evidence of toxicity to normal organs and tissues. DaZen’s research has also shown that its targeted drugs and technologies can overcome therapeutic resistance by cancer cells to a broad spectrum of therapies, including chemotherapy, hormonal therapy, and targeted therapies with tyrosine kinase ...
-
Manufactured by Panagene Inc.based in SOUTH KOREA
KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, biliary tract cancer and thyroid cancer. The existence of KRAS mutations is often related with a prognostic marker to drug response. For example, KRAS mutation is considered a strong prognostic marker for drug response of tyrosine kinase ...
-
Manufactured by Panagene Inc.based in SOUTH KOREA
to find lung cancer in the early stage and is diagnosed as lung cancer when it is already progressed. So the prognosis tends to be bad. It is known that the patients with EGFR mutation show very high drug responses against EGFR tyrosine kinase inhibitor (TKI) such as Gefitinib (Iressa, AstraZenca) and Erlotinib (Tarceba, Roche). We expect that ...
-
Manufactured by AVEO Pharmaceuticals, Inc.based in USA
FOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.1,2 AVEO received U.S. Food and Drug Administration (FDA) ...
-
Manufactured by Clearside Biomedicalbased in USA
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal use. Axitinib is a tyrosine kinase inhibitor (TKI) currently approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. We believe this broad VEGF ...
-
Manufactured by ViennaLab Diagnostics GmbHbased in AUSTRIA
NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment. The EGFR XL StripAssay® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI ...
-
based in USA
Inhaled Imatinib for PAH: We have advanced inhaled imatinib, AER-901, into the clinic for the treatment of patients with pulmonary arterial hypertension (PAH). The Phase 1 trial is currently ...
-
Manufactured by ViennaLab Diagnostics GmbHbased in AUSTRIA
A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the EGFR ...
-
Manufactured by MorphoSys AGbased in GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...
-
Manufactured by Amoy Diagnostics Co., Ltd.based in CHINA
Lung cancer is one of the most common malignant tumor, and 80~85% of lung cancers are non-small cell lung cancer (NSCLC). There are many driver mutations in NSCLC. The frequency of mutations in patients with NSCLC for the EGFR gene is 10~35%, for KRAS 15?25%, for BRAF1-4%, for NRAS is 1%, for HER2 2-4%, and for PIK3CA 1-3%. About 3-7% of NSCLC patients have gene fusion in ALK, 2% in ROS1, and 1% ...
-
Manufactured by GENCURIXbased in SOUTH KOREA
Chemotherapy drugs have many side effects such as reduction in white blood cells, hair loss, vomiting because they attack rapidly growing cells without separating cancer cells from normal cells. However targeted therapy drugs have less side effects because they detect and attack specific targets that exist only in cancer ...
-
Manufactured by Amoy Diagnostics Co., Ltd.based in CHINA
Neurotrophic tropomyosin-related kinase (NTRK) is a group of high affinity nerve growth factor (NGF) receptors, including tropomyosin receptor kinases (Trk) A, B, and C which are encoded by NTRK1, NTRK2, and NTRK3 genes, respectively. NTRK proteins, upon NGF ligand binding, function in the phosphorylation of members of the RAS/MAPK, PI3K/AKT, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you